First-Line Anlotinib Treatment for Soft Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-label, Single-arm, Phase 2 Clinical Trial.
Tao LiYing DongYongzhong WeiShoufeng WangYunXia LiuJia ChenWenhua XiongNong LinXin HuangMeng LiuXiaobo YanZhao-Ming YeBinghao LiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
The findings suggest a potential benefit in employing front-line anlotinib to treat patients with STS, who are not eligible for cytotoxic chemotherapy. Of note, the clinical outcomes for the LPS subgroup of patients were encouraging.